A Review on Notch Signaling and Colorectal Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) has one of the highest mortality rates despite the advancement of treatment options. Aggressive CRC remains difficult to treat owing to the activation of oncogenic signaling pathways such as the Notch signaling pathway. The role of Notch receptors varies according to the difference in their structures; in particular, aberrant activation of Notch1 has been attributed to the severity of CRC. Notch1 activation in CRC is inhibited by small molecule inhibitors that target γ-secretase, an enzyme responsible for the third and last cleavage step of Notch receptors. γ-Secretase also produces the intracellular domain that finally carries out cellular functions by activating downstream effectors. However, most inhibitors block γ-secretase non-selectively and cause severe toxicity. Plant-source-derived small molecules, monoclonal antibodies, biological molecules (such as SiRNAs), and compounds targeting the Notch1 receptor itself or the downstream molecules such as HES1 are some of the options that are in advanced stages of clinical trials. The Negative Regulatory Region (NRR), which plays a central role in the transduction of Notch1 signaling in the event of ligand-dependent and ligand-independent Notch1 processing is also being targeted specifically by monoclonal antibodies (mAbs) to prevent aberrant Notch1 activation. In this review, we discuss the role of Notch1 in CRC, particularly its metastatic phenotype, and how mutations in Notch1, specifically in its NRR region, contribute to the aberrant activation of Notch1 signaling, which, in turn, contributes to CRC pathogenesis. We also discuss prevailing and emerging therapies that target the Notch1 receptor and the NRR region, and we highlight the potential of these therapies in abrogating Notch signaling and, thus, CRC development and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“Despite an apparent decrease in CRC-related morbidity in the past decade, metastatic CRC remains difficult to treat and thus has high mortality rates [2,3].”
BackgroundRole of Notch signaling in colorectal cancer
Qiao, L., & Wong, B. C. Y. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp236 · Cited by 154
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy171 · Cited by 138 · cited 1×
“For example, OMP-52M51, in a phase I dose-escalation trial (NCT01778439), showed limited antitumor efficacy [86], while a clinical trial for OMP-21M18/Demcizumab was stopped due to a lack of clinical responses [87].”
Background
Cited by
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., et al. (2023) · Cancers · doi:10.3390/cancers15051471 · Cited by 27
“Both HH-GLI and NOTCH pathways were described as deregulated and associated with poor prognosis in CRC [18,19].”
BackgroundNotch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
Brisset, M., Mehlen, P., Meurette, O., & Hollande, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231416 · Cited by 20
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116220 · Cited by 18
Metadata
- Authors
- Tyagi, A., Sharma, A. K., & Damodaran, C.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-06-25
- Volume
- 9
- Issue
- 6
- Pages
- 1549
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3037705365
- Cited by
- 179
- References
- 3
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.